S
SpringWorks Therapeutics
Clinical-stage biopharmaceutical company that identifies and advances promising science and pioneers efficient pathways
About SpringWorks Therapeutics
SpringWorks Therapeutics is a clinical stage biopharmaceutical company focused on developing and commercializing precision medicines for patients with rare diseases and cancer. The company employs a precision medicine approach, which means they tailor treatments based on the genetic and molecular profile of the disease. This approach aims to improve the efficacy and safety of treatments for underserved patient populations suffering from devastating conditions. SpringWorks operates in the biopharmaceutical market, targeting both rare diseases and oncology. Their business model involves acquiring, developing, and commercializing innovative therapies. Revenue is generated through the successful development and commercialization of these therapies, often in collaboration with other pharmaceutical companies. The company serves a niche market of patients with specific genetic profiles, offering them potentially life-changing treatments that are not widely available. SpringWorks is actively involved in clinical trials, including Phase 1b and 2 studies, to evaluate the efficacy and safety of their drug candidates.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2019
Open roles
SpringWorks Therapeutics in the New York City ecosystem
The SpringWorks Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Pfizer
Bain Capital
OrbiMed
LifeArc
Perceptive Advisors
ArrowMark Partners
Samsara BioCapital
GSK
Series B and later8 investors entered at this stage
- GSGSK
Perceptive Advisors- ECEcoR1 Capital
- APArrowMark Partners
- DEDeerfield
- SBSamsara BioCapital
- BCBoxer Capital
- INInvus
Source: Dealroom Talent Intelligence.
Patents
58 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See SpringWorks Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Merck KGaA to buy Silence Therapeutics for $1.3B in cash
Merck KGaA acquires SpringWorks (July 2025)
